Type
Internal restructuring
Country
Belgium
Region
RĂ©gion Wallonne; Prov. Hainaut; Arr. Charleroi
Location of affected unit(s)
Gosselies
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.2 - Manufacture Of Pharmaceutical Preparations

104 - 347 jobs
Number of planned job losses
Job loss
Announcement Date
13 October 2023
Employment effect (start)
14 October 2023
Foreseen end date

Description

Catalent, an American multinational pharmaceutical company specialised in the development and production in cell therapy, has announced it will be reorganising its facility in Gosselies. The company management has announced it will dismiss approximately 104 of 347 employees within the facility.

The restructuring has been caused by newer regulation introduced, problems in the supply chain and the rising cost of salaries. The broader context is that the sector is currently undergoing difficulties, in addition the company is faced with the postponement of investments by customers, as well as the announcement of the end of programmes by 2 of their main customers.


Sources

Citation

Eurofound (2023), Catalent, Internal restructuring in Belgium, factsheet number 200389, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/200389.